Antithrombotic Anticoagulants articles

pacientes anticoagulados por fibrilación auricular que reciben angioplastia tratamiento

The Best Anticoagulant Agent for AF After TAVR

The Best Anticoagulant Agent for AF After TAVR

Direct anticoagulant agents were associated with lower long-term mortality in patients with atrial fibrillation (AF) discharged after transcatheter aortic valve replacement (TAVR), compared with classic vitamin K antagonists. The purpose of this paper published in JACC Interv was to compare long-term results between classic vitamin K antagonists and novel direct anticoagulant agents in patients with

Historia natural de la infección asintomática por COVID-19

Major Cause of Myocardial Injury by COVID-19

The most common cause of myocardial necrosis in patient undergoing COVID-19 infection is microthrombi. These microthrombi resulted quite different in composition vs. thrombi obtained from COVID-19 negative patients and thrombi obtained from infected patients with ACS.  Myocardial injury is common in patients hospitalized for COVID-19 and has worse prognosis. Regardless its frequency, the mechanism and

Seguridad de combinar los nuevos anticoagulantes y la doble antiagregación

AAS vs Warfarin in Low Risk TAVR

We are still discussing the adequate antithrombotic scheme after transcatheter aortic valve replacement (TAVR). Additionally, we are treating a much wider array of patients ranging from low risk to inoperable.  And there is yet one more important point: hypo-attenuated leaflet thickening diagnosed by CT. We are still unaware of the impact they have on device

AHA 2020 | RIVER: Rivaroxaban como alternativa a la warfarina en pacientes con fibrilación auricular y protesis mitral biológica

AHA 2020 | RIVER: Rivaroxaban as Alternative to Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Mitral Valve

Rivaroxaban seems to be a reasonable alternative to warfarin in patients with atrial fibrillation and bioprosthetic mitral valve. These results arise from the RIVER Study presented at the American Heart Association (AHA) 2020 Congress and simultaneously published in the New England Journal of Medicine (NEJM). After 5 years of follow-up, rivaroxaban reached the non-inferiority criterion

ESC 2020 | El Rivaroxaban puede reducir los eventos cardíacos, cerebrales y periféricos

ESC 2020 | Rivaroxaban Might Reduce Cardiac Cerebral and Peripheral Events

Adding rivaroxaban to the standard treatment might reduce events incidence in lower limbs, heart, and brain, in patients with peripheral vascular disease undergoing revascularization.   These new data resulted from the analysis of the VOYAGER PAD subgroups and were presented at the virtual ESC 2020. The COMPASS study had reached similar conclusions using 2.5 mg rivaroxaban

Sangrados mayores en pacientes con AAS más rivaroxabán

Impact on Mortality with Rivaroxaban after Discharge

Extending thromboembolic prophylaxis with rivaroxaban in patients hospitalized for heart conditions reduce fatal and thromboembolic events by 28% without major bleeding payback.   Patients hospitalized for heart conditions are at risk of thromboembolic events, and this is why inhospital prophylaxis (in general with low molecular weight heparin) is within the standard treatment. It was not

Balancear el riesgo de sangrado vs trombótico para definir el tiempo de doble antiagregación

Antiaggregation vs. Anticoagulation after Peripheral PCI

The truth is this question has no clear answer and what with do with peripheral stenting is transfer the evidence we have on coronary stenting, given the lack of standards and poor reporting on antithrombotic therapy outcomes in randomized studies on endovascular intervention.  Heterogeneity is worse when it comes to venous territory. Some time ago

ACC 2020 Virtual | PRONOMOS: Rivaroxaban superior a la enoxaparina en cirugías ortopédicas

Virtual ACC 2020 | PRONOMOS: Rivaroxaban Superior to Enoxaparin in Orthopedic Surgery

According to this new study presented virtually at the suspended American College of Cardiology (ACC) 2020 Scientific Session and published simultaneously in the New England Journal of Medicine (NEJM), rivaroxaban is more effective than enoxaparin in preventing venous thromboembolism during a period of immobilization after nonmajor orthopedic surgery of a lower limb. After an orthopedic

ACC 2020 Virtual | POPULAR TAVI: ¿anticoagulación sin clopidogrel post TAVI?

Virtual ACC 2020 | POPULAR TAVR: Post TAVR Anticoagulation without Clopidogrel?

In patients undergoing transcatheter aortic valve replacement (TAVR) that also required anticoagulation for another indication (mostly atrial fibrillation), the incidence of major bleeding between month 1 and 12 was lower in those receiving only anticoagulation instead of anticoagulation + clopidogrel.  The present study presented as part of the scientific sessions at the virtual ACC 2020,

ACC 2020 | Antídoto para sangrados con riesgo de vida bajo los nuevos anticoagulantes

Virtual ACC 2020 | Antidote for Life-Threatening Bleeding with New Anticoagulant Agents

Among patients hospitalized with life-threatening or uncontrolled bleeding under treatment with direct factor Xa inhibition, anticoagulation reversal with andexanet alfa (Andexxa) was associated with low mortality rates. These promising results have multiple limitations, particularly the lack of definition on bleeding severity. One of the studies testing the new antidote used propensity-score matching, and there were lower